Rabeprazole

Rabeprazole

SCHEMBL491362

COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C.[Na]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.60
CYP2C9 P11712 4/20 0.60
WDR5 P61964 4/20 0.60
LMNA P02545 4/20 0.60
ENGASE Q8NFI3 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MAPT P10636 3/20 0.60
DDAH1 O94760 2/20 0.60
ADORA3 P0DMS8 2/20 0.60
HPGD P15428 2/20 0.60
TBXA2R P21731 2/20 0.60
NPY1R P25929 2/20 0.60
ADORA1 P30542 2/20 0.60
OPRM1 P35372 2/20 0.60
HTR3A P46098 2/20 0.60
FASN P49327 2/20 0.60
SARM1 Q6SZW1 2/20 0.60
ABCG2 Q9UNQ0 2/20 0.60
HTR1A P08908 1/20 0.60
IDE P14735 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dexrabeprazole SCHEMBL30019061 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL29493315 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL29374701 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL23337 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL23336 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL29833678 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL4946138 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Dexrabeprazole SCHEMBL30945135 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL29360086 0.99 KMT2A (0.61) KMT2ACYP2C9WDR5LMNAENGASE
Rabeprazole SCHEMBL1559483 0.98 KMT2A (0.60) KMT2ACYP2C9WDR5LMNAENGASE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1607395-B1 PROCESS FOR THE PREPARATION OF AMORPHOUS RABEPRAZOLE SODIUM SALT EISAI R&D MAN CO LTD (JP) 2011-05-04 EP claimed
US-7754887-B2 Process for production of sulfoxide derivatives or salts thereof in the amorphous state EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-07-13 US claimed
EP-1851212-B1 NEW PROCESS FOR SYNTHESIS OF PROTON PUMP INHIBITORS CIPLA LTD (IN) 2010-07-07 EP claimed
US-20080214828-A1 PROCESS FOR PRODUCTION OF SULFOXIDE DERIVATIVES OR SALTS THEREOF IN THE AMORPHOUS STATE TSUJII MASAHIKO 2008-09-04 US claimed
US-20060178406-A1 Process for production of sulfoxide derivatives or salts thereof in the amorphous state EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-08-10 US claimed
EP-1607395-A1 PROCESS FOR PRODUCTION OF SULFOXIDE DERIVATIVES OR SALTS THEREOF IN THE AMORPHOUS STATE Eisai Co., Ltd. (JP) 2005-12-21 EP claimed
US-20050234103-A1 Crystalline forms of rabeprazole sodium DR. REDDY'S LABORATORIES, INC. 2005-10-20 US claimed
EP-1487820-A1 CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM Dr. Reddy's Laboratories Ltd. (IN) 2004-12-22 EP claimed
EP-1000943-B1 Sulfoxide compounds and acetone complexes, and a process for producing the same EISAI CO LTD (JP) 2004-02-18 EP claimed
WO-2003082858-A1 CRYSTALLINE FORMS OF RABEPRAZOLE SODIUM DR. REDDY'S LABORATORIES LIMITED (IN) 2003-10-09 WO claimed
US-6545024-B1 Complexing acetone with sulfoxides such as Rabeprazole, Lansoprazole, Omeprazole or Pantoprazole; inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines EISAI CO., LTD. (JP) 2003-04-08 US claimed
US-6180652-B1 ANTIULCER, ANTISECRETORY AGENTS EISAI CO., LTD. (JP) 2001-01-30 US claimed
EP-1000943-A1 Sulfoxide compounds and acetone complexes, and a process for producing the same Eisai Co., Ltd. (JP) 2000-05-17 EP claimed
JP-1290628-A None JP disclosed
CN-117949559-A Method for testing related substances in sodium rabeprazole enteric-coated tablets 湖南九典制药股份有限公司 2024-04-30 CN disclosed
CN-113069428-B Preparation method of rabeprazole sodium enteric-coated tablets 珠海润都制药股份有限公司 2023-02-10 CN disclosed
EP-0342522-B1 PERORAL PREPARATION OF AN ACID-UNSTABLE COMPOUND Eisai Co., Ltd. (JP) 1991-12-18 EP disclosed
US-5035899-A Benzimidazole antiulcer agents, protective coatings on tablets, stabilization EISAI CO., LTD. (JP) 1991-07-30 US disclosed
EP-0342522-A1 Peroral preparation of an acid-unstable compound Eisai Co., Ltd. (JP) 1989-11-23 EP disclosed
JP-H01290628-A INTERNAL DRUG PREPARATION OF COMPOUND UNSTABLE TO ACID EISAI CO LTD 1989-11-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234103-A1 Crystalline forms of rabeprazole sodium RAB7A, RABL3, RAB27A KMT2A 3014/4885CYP2C9 79/4885WDR5 1450/4885
US-20060178406-A1 Process for production of sulfoxide derivatives or salts thereof in the amorphous state MSRB3, SCLY, AS3MT KMT2A 804/4885CYP2C9 1086/4885WDR5 1826/4885
US-20080214828-A1 PROCESS FOR PRODUCTION OF SULFOXIDE DERIVATIVES OR SALTS THEREOF IN THE AMORPHOUS STATE MSRB3, MSMO1, SCLY KMT2A 874/4885CYP2C9 879/4885WDR5 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.